Literature DB >> 25991062

Early lethality and neuronal proteinopathy in mice expressing cytoplasm-targeted FUS that lacks the RNA recognition motif.

Hannah K Robinson1, Alexey V Deykin2, Evgeny V Bronovitsky3, Ruslan K Ovchinnikov3, Alexey A Ustyugov1,3, Tatyana A Shelkovnikova1,3, Michail S Kukharsky3, Tatyana G Ermolkevich2, Igor L Goldman2, Elena R Sadchikova2, Elena A Kovrazhkina4, Sergey O Bachurin3, Vladimir L Buchman1, Natalia N Ninkina1,3.   

Abstract

Mutations to the RNA binding protein, fused in sarcoma (FUS) occur in ∼5% of familial ALS and FUS-positive cytoplasmic inclusions are commonly observed in these patients. Altered RNA metabolism is increasingly implicated in ALS, yet it is not understood how the specificity with which FUS interacts with RNA in the cytoplasm can affect its aggregation in vivo. To further understand this, we expressed, in mice, a form of FUS (FUS ΔRRMcyt) that lacked the RNA recognition motif (RRM), thought to impart specificity to FUS-RNA interactions, and carried an ALS-associated point mutation, R522G, retaining the protein in the cytoplasm. Here we report the phenotype and results of histological assessment of the brain of transgenic mice expressing this isoform of FUS. Results demonstrated that neuronal expression of FUS ΔRRMcyt caused early lethality often preceded by severe tremor. Large FUS-positive cytoplasmic inclusions were found in many brain neurons; however, neither neuronal loss nor neuroinflammatory response was observed. In conclusion, the extensive FUS proteinopathy and severe phenotype of these mice suggests that affecting the interactions of FUS with RNA in vivo may augment its aggregation in the neuronal cytoplasm and the severity of disease processes.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; RNA binding; RNA recognition motif; fused in sarcoma; transgenic animals

Mesh:

Substances:

Year:  2015        PMID: 25991062      PMCID: PMC4811325          DOI: 10.3109/21678421.2015.1040994

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  44 in total

Review 1.  Stress granules: the Tao of RNA triage.

Authors:  Paul Anderson; Nancy Kedersha
Journal:  Trends Biochem Sci       Date:  2008-03       Impact factor: 13.807

2.  TDP-43 and FUS RNA-binding proteins bind distinct sets of cytoplasmic messenger RNAs and differently regulate their post-transcriptional fate in motoneuron-like cells.

Authors:  Claudia Colombrita; Elisa Onesto; Francesca Megiorni; Antonio Pizzuti; Francisco E Baralle; Emanuele Buratti; Vincenzo Silani; Antonia Ratti
Journal:  J Biol Chem       Date:  2012-03-16       Impact factor: 5.157

3.  Novel FUS/TLS mutations and pathology in familial and sporadic amyotrophic lateral sclerosis.

Authors:  Christopher Hewitt; Janine Kirby; J Robin Highley; Judith A Hartley; Rachael Hibberd; Hannah C Hollinger; Tim L Williams; Paul G Ince; Christopher J McDermott; Pamela J Shaw
Journal:  Arch Neurol       Date:  2010-04

4.  Loss of fused in sarcoma (FUS) promotes pathological Tau splicing.

Authors:  Denise Orozco; Sabina Tahirovic; Kristin Rentzsch; Benjamin M Schwenk; Christian Haass; Dieter Edbauer
Journal:  EMBO Rep       Date:  2012-06-19       Impact factor: 8.807

5.  TLS/FUS (translocated in liposarcoma/fused in sarcoma) regulates target gene transcription via single-stranded DNA response elements.

Authors:  Adelene Y Tan; Todd R Riley; Tristan Coady; Harmen J Bussemaker; James L Manley
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-29       Impact factor: 11.205

6.  ALS-associated fused in sarcoma (FUS) mutations disrupt Transportin-mediated nuclear import.

Authors:  Dorothee Dormann; Ramona Rodde; Dieter Edbauer; Eva Bentmann; Ingeborg Fischer; Alexander Hruscha; Manuel E Than; Ian R A Mackenzie; Anja Capell; Bettina Schmid; Manuela Neumann; Christian Haass
Journal:  EMBO J       Date:  2010-07-06       Impact factor: 11.598

7.  Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43).

Authors:  Eva Bentmann; Manuela Neumann; Sabina Tahirovic; Ramona Rodde; Dorothee Dormann; Christian Haass
Journal:  J Biol Chem       Date:  2012-05-04       Impact factor: 5.157

8.  Selective pattern of motor system damage in gamma-synuclein transgenic mice mirrors the respective pathology in amyotrophic lateral sclerosis.

Authors:  Owen M Peters; Steven Millership; Tatyana A Shelkovnikova; Ileana Soto; Lora Keeling; Anthony Hann; Nicholas Marsh-Armstrong; Vladimir L Buchman; Natalia Ninkina
Journal:  Neurobiol Dis       Date:  2012-06-30       Impact factor: 5.996

9.  Position-dependent FUS-RNA interactions regulate alternative splicing events and transcriptions.

Authors:  Shinsuke Ishigaki; Akio Masuda; Yusuke Fujioka; Yohei Iguchi; Masahisa Katsuno; Akihide Shibata; Fumihiko Urano; Gen Sobue; Kinji Ohno
Journal:  Sci Rep       Date:  2012-07-24       Impact factor: 4.379

10.  FUS transgenic rats develop the phenotypes of amyotrophic lateral sclerosis and frontotemporal lobar degeneration.

Authors:  Cao Huang; Hongxia Zhou; Jianbin Tong; Han Chen; Yong-Jian Liu; Dian Wang; Xiaotao Wei; Xu-Gang Xia
Journal:  PLoS Genet       Date:  2011-03-03       Impact factor: 5.917

View more
  6 in total

Review 1.  TDP-43/FUS in motor neuron disease: Complexity and challenges.

Authors:  Erika N Guerrero; Haibo Wang; Joy Mitra; Pavana M Hegde; Sara E Stowell; Nicole F Liachko; Brian C Kraemer; Ralph M Garruto; K S Rao; Muralidhar L Hegde
Journal:  Prog Neurobiol       Date:  2016-09-28       Impact factor: 11.685

2.  Low Level of Expression of C-Terminally Truncated Human FUS Causes Extensive Changes in the Spinal Cord Transcriptome of Asymptomatic Transgenic Mice.

Authors:  Ekaterina A Lysikova; Sergei Funikov; Alexander P Rezvykh; Kirill D Chaprov; Michail S Kukharsky; Aleksey Ustyugov; Alexey V Deykin; Ilya M Flyamer; Shelagh Boyle; Sergey O Bachurin; Natalia Ninkina; Vladimir L Buchman
Journal:  Neurochem Res       Date:  2020-03-11       Impact factor: 3.996

Review 3.  Pathogenesis of FUS-associated ALS and FTD: insights from rodent models.

Authors:  Matthew Nolan; Kevin Talbot; Olaf Ansorge
Journal:  Acta Neuropathol Commun       Date:  2016-09-06       Impact factor: 7.801

4.  Antiviral Immune Response as a Trigger of FUS Proteinopathy in Amyotrophic Lateral Sclerosis.

Authors:  Tatyana A Shelkovnikova; Haiyan An; Lucy Skelt; John S Tregoning; Ian R Humphreys; Vladimir L Buchman
Journal:  Cell Rep       Date:  2019-12-24       Impact factor: 9.995

Review 5.  ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?

Authors:  Rita Mejzini; Loren L Flynn; Ianthe L Pitout; Sue Fletcher; Steve D Wilton; P Anthony Akkari
Journal:  Front Neurosci       Date:  2019-12-06       Impact factor: 4.677

Review 6.  RNA Is a Double-Edged Sword in ALS Pathogenesis.

Authors:  Benjamin L Zaepfel; Jeffrey D Rothstein
Journal:  Front Cell Neurosci       Date:  2021-07-19       Impact factor: 5.505

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.